METHOD OF ELECTRICALLY DETECTING A BIOLOGICAL ANALYTE MOLECULE

• US 20100194409A1
• Filed: 08/14/2007
• Published: 08/05/2010
• Est. Priority Date: 08/16/2006
• Status: Abandoned Application

• Current Assignee: Agency For Science Technology and Research (Government of Singapore)
• Original Assignee: Agency For Science Technology and Research (Government of Singapore)
• Inventors: Gao, Zhiqiang, Fan, Yi, Chen, Xiantong, Kong, Jinming
• Application Number:
  US12/377,404
• Publication Number:
  US 20100194409A1
• Time in Patent Office: Days
• US Class Current: 324/693
• CPC Class Codes: C12Q 1/6825 Nucleic acid detection involving sensors
• CPC Class Codes: C12Q 2563/116 electrical properties of nucleic acids, e.g. impedance, conductivity or resistance
• CPC Class Codes: C12Q 2563/155 Particles of a defined size, e.g. nanoparticles
• CPC Class Codes: C12Q 2565/107 Alteration in the property of hybridised versus free label oligonucleotides
• CPC Class Codes: C12Q 2565/607 being a sensor, e.g. electrode
• CPC Class Codes: G01N 33/5438 Electrodes

Abstract

The invention provides a method of electrically detecting a biological analyte molecule by means of a pair of electrodes. The electrodes are arranged at a distance from one another within a sensing zone. A capture molecule, which has an affinity to the analyte molecule and which is capable of forming a complex with the analyte molecule, is immobilised on an immobilisation unit. The immobilisation unit is contacted with a solution suspected to comprise the analyte molecule. The analyte molecule is allowed to form a complex with the capture molecule. The invention also provides a probe defined by a nanoparticulate tag that comprises or consists of electrically conducting matter that is capable of chemically interacting with the analyte molecule. In the method of the invention the electrically conducting nanoparticulate tag is added. Thereby the electrically conducting nanoparticulate tag is allowed to associate to the complex formed between the capture molecule and the analyte molecule. The presence of the analyte molecule is determined based on an electrical characteristic, influenced by the electrically conducting nanoparticulate tag, of a region in the sensing zone.

Claims

1. A method of electrically detecting a biological analyte molecule by means of a pair of electrodes, wherein said electrodes are arranged at a distance from one another and wherein said pair of electrodes is arranged within a sensing zone, the method comprising:

(a) immobilising on an immobilisation unit a capture molecule, wherein the capture molecule has an affinity to the analyte molecule and is capable of forming a complex with the analyte molecule;

(b) contacting the immobilisation unit with a solution suspected to comprise the analyte molecule;

(c) allowing the analyte molecule to form a complex with the capture molecule;

(d) adding an electrically conducting nanoparticulate tag, wherein the electrically conducting nanoparticulate tag comprises or consists of electrically conducting matter that is capable of chemically interacting with the analyte molecule, thereby allowing said electrically conducting nanoparticulate tag to associate to the complex formed between said capture molecule and said analyte molecule;

(e) determining the presence of the analyte molecule based on an electrical characteristic of a region in the sensing zone, wherein the electrical characteristic is influenced by the electrically conducting nanoparticulate tag.

2. The method of claim 1, wherein (e) comprises comparing the result of d of the electrical measurement with that of a control measurement.

3. The method of claim 1 or 2, wherein the region in the sensing zone, based on the electrical characteristic of which an electrical measurement is carried out in (e), is a region in between the electrodes.

4. The method of any one of claims 1-3, wherein (a) comprises providing the immobilisation unit.

5. The method of any one of claims 1-4, wherein said biological analyte molecule is one of a nucleic acid molecule, an oligonucleotide, a protein, an oligopeptide, a polysaccharide an oligosaccharide and any composition thereof.

6. The method of any one of claims 1-5, wherein the electrical characteristic influenced by the electrically conducting nanoparticulate tag is detected by measuring any one of a conductance, a voltage, a current, a capacitance, and a resistance.

7. The method of any one of claims 1-6, wherein (f) further comprises exposing the immobilisation unit to an electric field.

8. The method of claim 7, wherein said electric field is generated at least one electrode of said pair of electrodes.

9. The method of any one of claims 1-8, wherein the sensing zone is defined by the zone in which an electric field of said pair of electrodes is effective.

10. The method of any one of claims 1-9, wherein the immobilisation unit is arranged in between the pair of electrodes.

11. The method of claim 10, wherein the immobilisation unit is arranged in a gap defined by the pair of electrodes.

12. The method of any one of claims 1-11, wherein the immobilisation unit is comprised on or conductively connected to an electrode.

13. The method of any one of claims 1-12, wherein the capture molecule is selected from the group consisting of a nucleic acid molecule, an oligonucleotide, a protein, an oligopeptide, a polysaccharide, an oligosaccharide, a synthetic polymer, a drug candidate molecule, a drug molecule, a drug metabolite, a metal ion, and a vitamin.

14. The method of claim 13, wherein the nucleic acid molecule defining the capture molecule is one of a DNA molecule, a RNA molecule and a PNA molecule.

15. The method of claim 13 or 14, wherein the nucleic acid molecule is a single-stranded capture molecule or comprises a single stranded region.

16. The method of claim 15, wherein the analyte molecule is a nucleic acid, and wherein the capture molecule has a nucleotide sequence that is at least partially complementary to at least a portion of a strand of the analyte nucleic acid molecule.

17. The method of claim 15 or 16, wherein the capture molecule has a nucleic acid sequence of a length of about 7 to about 30 bp

18. The method of claim 17, wherein the nucleic acid sequence is of a length of about 10 to about 20 bp.

19. The method of any one of claims 15-18, wherein allowing the analyte molecule to form a complex with the capture molecule comprises:

allowing the analyte molecule to hybridise to the capture molecule, the capture molecule being defined by a single-stranded nucleic acid molecule, thereby allowing the formation of a complex between the capture molecule and the analyte molecule.

20. The method of any one of claims 5-19, wherein the analyte molecule comprises a pre-defined sequence.

21. The method of any one of claims 5-20, wherein the analyte molecule is a DNA molecule or an RNA molecule.

22. The method of any one of claims 5-21, wherein the analyte molecule is a nucleic acid molecule that comprises at least one single-stranded region.

23. The method of claim 20, wherein the predefined sequence is a single-stranded region of a nucleic acid molecule.

24. The method of any one of claims 17-23, wherein the capture molecule is a single-stranded DNA molecule or a single-stranded RNA molecule, and wherein any such capture molecule that does not hybridise to an analyte molecule, is removed from the immobilisation unit.

25. The method of any one of claims 5-24, wherein the analyte molecule is or comprises an oligopeptide or a protein and said capture molecule is a receptor molecule for said polypeptide or protein and wherein said oligopeptide or protein and the receptor molecule define a specific binding pair.

26. The method of claim 25, wherein the receptor molecule is selected from the group consisting of an immunoglobulin, a mutein based on a polypeptide of the lipocalin family, a glubody, a domain antibody, a protein based on the ankyrin or crystalline scaffold, a protein based on a plurality of low-density lipoprotein receptor class A (LDLR-A) domains, an AdNectin, a tetranectin, an avimer, the T7 epitope, maltose binding protein, the HSV epitope of herpes simplex virus glycoprotein D, the hemagglutinin epitope, and the myc epitope of the transcription factor c-myc, an oligonucleotide, an oligosaccharide, an oligopeptide, biotin, dinitrophenol, digoxigenin and a metal chelator.

27. The method of claim 25 or 26, wherein the polypeptide or the protein comprises the amino acid sequence Arginine-X-X-Arginine, wherein X is any amino acid.

28. The method of any one of claims 1-27, wherein the electrically conducting nanoparticulate tag is selected from the group consisting of a nanocrystal, a nanosphere, a nanorod, a nanotube, a nanowire and a nanocup.

29. The method of claim 28, wherein adding the nanoparticulate tag comprises adding a plurality of electrically conducting nanoparticles,

thereby allowing the plurality of electrically conducting nanoparticles to associate to the complex formed between said capture molecule and said analyte molecule,

such that an electrically conducting network of said electrically conducting nanoparticles is formed, wherein the network is associated with the complex formed between the capture molecule and the analyte molecule.

30. The method of claim 29, wherein the formed electrically conducting network of said electrically conducting nanoparticles is conductively connected to the immobilisation unit.

31. The method of any one of claims 1-30, wherein the electrically conducting matter comprised in the electrically conducting nanoparticulate tag is at least one of a metal, a metalloid, carbon and a polymer.

32. The method of claim 31, wherein said metal or a metalloid comprised in the electrically conducting nanoparticulate tag is able to associate to the analyte molecule via negative charges present on the surface of the analyte molecule.

33. The method of claim 31 or 32, wherein the metalloid is a metal oxide or a metal hydroxide.

34. The method of claim 33, wherein the metalloid has an affinity to phosphate and/or phosphonate and wherein the analyte molecule is defined by a nucleic acid molecule, thereby allowing the nanoparticulate tag to associate to a nucleic acid molecule at the backbone thereof.

35. The method of claim 33 or 34, wherein the metal oxide is selected from the group consisting of indium tin oxide, titanium oxide, tantalum oxide, copper oxide and zinc oxide.

36. The method of claim 33 or 34, wherein the metal hydroxide is selected from the group consisting of aluminium hydroxide, titanium hydroxide, copper hydroxide and gold hydroxide.

37. The method of claims 31-36, wherein the metal or a metalloid is capable of forming a complex with the analyte molecule via a coordinative bond.

38. The method of claims 30-37, wherein the nanoparticulate tag further comprises a dopant and/or an activation agent.

39. The method of claim 37, wherein the coordinative bond is formed by a reaction with said activation agent.

40. The method of claim 38 or 39, wherein the activation agent is a transition metal compound or a metalloid compound.

41. The method of claim 40, wherein the transition metal compound is selected from the group consisting of a zirconium compound, a titanium compound and a niobium compound.

42. The method of claim 40, wherein the metalloid compound is a silicon compound.

43. The method of claim 41, wherein the zirconium compound is zirconyl chloride.

44. The method of claim 43, wherein the nanoparticulate tag comprises or consists of zirconyl chloride activated indium tin oxide.

45. The method of any one of claims 1-44, wherein (b) comprises immobilising a blocking agent on the immobilisation unit.

46. The method of any one of claims 1-45, wherein the analyte molecule is comprised in a sample selected from the group consisting of a soil sample, an air sample, an environmental sample, a cell culture sample, a bone marrow sample, a rainfall sample, a fallout sample, a space sample, an extraterrestrial sample, a sewage sample, a ground water sample, an abrasion sample, an archaeological sample, a food sample, a blood sample, a serum sample, a plasma sample, a urine sample, a stool sample, a semen sample, a lymphatic fluid sample, a cerebrospinal fluid sample, a naspharyngeal wash sample, a sputum sample, a mouth swab sample, a throat swab sample, a nasal swab sample, a bronchoalveolar lavage sample, a bronchial secretion sample, a milk sample, an amniotic fluid sample, a biopsy sample, a nail sample, a hair sample, a skin sample, a cancer sample, a tumour sample, a tissue sample, a cell sample, a cell lysate sample, a virus culture sample, a forensic sample, an infection sample, a nosocomial infection sample, a production sample, a drug preparation sample, a biological molecule production sample, a protein preparation sample, a lipid preparation sample, a carbohydrate preparation sample, a solution of a nucleotide, a solution of polynucleotide, a solution of a nucleic acid, a solution of a peptide, a solution of a polypeptide, a solution of an amino acid, a solution of a protein, a solution of a synthetic polymer, a solution of a biochemical composition, a solution of an organic chemical composition, a solution of an inorganic chemical composition, a solution of a lipid, a solution of a carbohydrate, a solution of a combinatory chemistry product, a solution of a drug candidate molecule, a solution of a drug molecule, a solution of a drug metabolite, a suspension of a cell, a suspension of a virus, a suspension of a microorganism, a suspension of a metal, a suspension of metal alloy, a solution of a metal ion, and any combination thereof.

47. A probe defined by an electrically conducting nanoparticulate tag, the electrically conducting nanoparticulate tag comprising or consisting of matter selected from the group consisting of a metal, a metalloid, carbon and a polymer, wherein said matter has an affinity to a biological analyte molecule and is capable of forming a complex with the analyte molecule.

48. The probe of claim 47, wherein the electrically conducting nanoparticulate tag comprises a plurality of nanoparticles of one of a nanocrystal, a nanosphere, a nanorod, a nanotube, a nanowire and a nanocup.

49. The probe of claim 47 or 48, wherein the biological analyte molecule is defined by one of a nucleic acid molecule, an oligonucleotide, a protein, an oligopeptide, a polysaccharide and an oligosaccharide.

50. The probe of any one of claims 47-49, wherein the metal or a metalloid is capable of forming a complex with the analyte molecule via negative charges present on the surface of the analyte molecule.

51. The probe of any one of claims 47-50, wherein the metalloid is a metal oxide or a metal hydroxide.

52. The probe of claim 51, wherein the metalloid has an affinity to phosphate and/or phosphonate, such that the nanoparticles associate to the backbone of a nucleic acid molecule.

53. The probe of claim 51 or 52, wherein the metal hydroxide is selected from the group consisting of aluminium hydroxide, titanium hydroxide, copper hydroxide and gold hydroxide.

54. The probe of claim 51 or 52, wherein the metal oxide is selected from the group consisting of indium tin oxide, titanium oxide, tantalum oxide, copper oxide and zinc oxide.

55. The probe of any one of claims 47-54, wherein the metal or a metalloid is capable of forming a complex with the analyte molecule via a coordinative bond.

56. The probe of any one of claims 47-55, wherein the nanoparticulate tag further comprises a dopant and/or an activation agent.

57. The probe of claim 55, wherein the coordinative bond has been obtained by a reaction with said activation agent.

58. The probe of claim 56 or 57, wherein the activation agent is a transition metal compound or a metalloid compound.

59. The probe of claim 58, wherein the metalloid compound is a silicon compound.

60. The probe of claim 58, wherein the transition metal compound is selected from the group consisting of a zirconium compound, a titanium compound and a niobium compound.

61. The probe of claim 60, wherein the zirconium compound is zirconyl chloride.

62. The probe of claim 61, wherein the nanoparticulate tag comprises or consists of zirconyl chloride activated indium tin oxide.

63. A kit for electrically detecting a biological analyte molecule, the kit comprising:

(a) a pair of electrodes, wherein said electrodes are arranged at a distance from one another and wherein said pair of electrodes is arranged within a sensing zone,

(b) an immobilisation unit arranged within said sensing zone;

(c) a capture molecule, wherein said capture molecule has an affinity to the analyte molecule and is capable of forming a complex with the analyte molecule; and

(d) an electrically conducting nanoparticulate tag, wherein the electrically conducting nanoparticulate tag comprises or consists of electrically conducting matter that is capable of chemically interacting with the analyte molecule.

64. The kit of claim 63, wherein the sensing zone is defined by the zone in which an electric field of said pair of electrodes is effective.

65. The kit of claim 63 or 64, wherein the immobilisation unit is arranged in between the pair of electrodes.

66. The kit of any one of claims 63-65, wherein the immobilisation unit is arranged in a gap defined by the pair of electrodes.

67. The kit of any one of claims 63-66, wherein the electrically conducting nanoparticulate tag comprises a plurality of nanoparticles of one of a nanocrystal, a nanosphere, a nanorod, a nanotube, a nanowire and a nanocup.

68. The kit of any one of claims 63-67, further comprising instructions for electrically detecting the biological analyte molecule.

69. The kit of any one of claims 63-68, wherein the electrically conducting matter comprised in the electrically conducting nanoparticle is at least one of a metal, a metalloid, carbon and a polymer.

70. The kit of any one of claims 63-69, wherein the capture molecule is one of a nucleic acid molecule, an oligonucleotide, a protein, an oligopeptide, a polysaccharide, an oligosaccharide, a synthetic polymer, a drug candidate molecule, a drug molecule, a drug metabolite, a metal ion, and a vitamin.